Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This was an open-label, Multi-center, randomized phase Ⅱ study. Patients with severe Alopecia
Areata were randomized to receive 50mg bid, 150mg qd or 200 mg qd of oral Jaktinib
Hydrochloride Tablets.